ID   S6A18_MOUSE             Reviewed;         615 AA.
AC   O88576; O88577; O88578; O88579; O88580; O88581; Q91XG6;
DT   29-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   27-MAR-2024, entry version 156.
DE   RecName: Full=Sodium-dependent neutral amino acid transporter B(0)AT3 {ECO:0000303|PubMed:19478081};
DE   AltName: Full=Sodium- and chloride-dependent transporter XTRP2;
DE   AltName: Full=Solute carrier family 6 member 18;
DE   AltName: Full=System B(0) neutral amino acid transporter AT3;
GN   Name=Slc6a18 {ECO:0000312|MGI:MGI:1336892};
GN   Synonyms=B0at3 {ECO:0000303|PubMed:19478081}, Xt2
GN   {ECO:0000303|PubMed:15121838}, Xtrp2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=9932288;
RA   Nash S.R., Giros B., Kingsmore S.F., Kim K.M., El-Mestikawy S., Dong Q.,
RA   Fumagalli F., Seldin M.F., Caron M.G.;
RT   "Cloning, gene structure, and genomic localization of an orphan transporter
RT   from mouse kidney with six alternatively-spliced isoforms.";
RL   Recept. Channels 6:113-128(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=15121838; DOI=10.1128/mcb.24.10.4166-4173.2004;
RA   Quan H., Athirakul K., Wetsel W.C., Torres G.E., Stevens R., Chen Y.T.,
RA   Coffman T.M., Caron M.G.;
RT   "Hypertension and impaired glycine handling in mice lacking the orphan
RT   transporter XT2.";
RL   Mol. Cell. Biol. 24:4166-4173(2004).
RN   [4]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   CLTRN.
RX   PubMed=19478081; DOI=10.1074/jbc.m109.011171;
RA   Singer D., Camargo S.M., Huggel K., Romeo E., Danilczyk U., Kuba K.,
RA   Chesnov S., Caron M.G., Penninger J.M., Verrey F.;
RT   "Orphan transporter SLC6A18 is renal neutral amino acid transporter
RT   B0AT3.";
RL   J. Biol. Chem. 284:19953-19960(2009).
RN   [5]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.
RX   PubMed=20377526; DOI=10.1042/bj20091667;
RA   Vanslambrouck J.M., Broeer A., Thavyogarajah T., Holst J., Bailey C.G.,
RA   Broeer S., Rasko J.E.;
RT   "Renal imino acid and glycine transport system ontogeny and involvement in
RT   developmental iminoglycinuria.";
RL   Biochem. J. 428:397-407(2010).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [7]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF ASP-21; GLN-25; HIS-50; TYR-72; GLY-78;
RP   LYS-90; SER-158; LEU-213; ARG-225; ASN-283; ASP-287; SER-296; MET-297;
RP   ILE-456; GLY-464; LEU-477; GLY-495; ASP-502 AND GLN-568.
RX   PubMed=26240152; DOI=10.1074/jbc.m115.648519;
RA   Fairweather S.J., Broeer A., Subramanian N., Tumer E., Cheng Q.,
RA   Schmoll D., O'Mara M.L., Broeer S.;
RT   "Molecular basis for the interaction of the mammalian amino acid
RT   transporters B0AT1 and B0AT3 with their ancillary protein collectrin.";
RL   J. Biol. Chem. 290:24308-24325(2015).
CC   -!- FUNCTION: Symporter that transports one amino acid molecule together
CC       with two sodium and one chloride ions in kidneys and plays a role in
CC       the neutral amino acids reabsorption (PubMed:19478081, PubMed:26240152,
CC       PubMed:20377526). Preferentially transports neutral amino acids such as
CC       L-glycine and L-alanine but also other neutral amino acids
CC       (PubMed:19478081, PubMed:26240152, PubMed:20377526). Required CLTRN for
CC       cell surface expression and for its amino acid transporter activity
CC       (PubMed:26240152, PubMed:20377526). The transport mechanism is pH-
CC       independent (PubMed:19478081). {ECO:0000269|PubMed:19478081,
CC       ECO:0000269|PubMed:20377526, ECO:0000269|PubMed:26240152}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-alanine(out) + 2 Na(+)(out) = chloride(in) +
CC         L-alanine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71311, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:57972;
CC         Evidence={ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:20377526,
CC         ECO:0000269|PubMed:26240152};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + glycine(out) + 2 Na(+)(out) = chloride(in) +
CC         glycine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:70691, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:57305;
CC         Evidence={ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:20377526};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-methionine(out) + 2 Na(+)(out) =
CC         chloride(in) + L-methionine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71303,
CC         ChEBI:CHEBI:17996, ChEBI:CHEBI:29101, ChEBI:CHEBI:57844;
CC         Evidence={ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:20377526};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-valine(out) + 2 Na(+)(out) = chloride(in) +
CC         L-valine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71307, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:57762;
CC         Evidence={ECO:0000269|PubMed:19478081};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-isoleucine(out) + 2 Na(+)(out) =
CC         chloride(in) + L-isoleucine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71299,
CC         ChEBI:CHEBI:17996, ChEBI:CHEBI:29101, ChEBI:CHEBI:58045;
CC         Evidence={ECO:0000269|PubMed:19478081};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-serine(out) + 2 Na(+)(out) = chloride(in) +
CC         L-serine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71315, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:33384;
CC         Evidence={ECO:0000269|PubMed:19478081};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + L-leucine(out) + 2 Na(+)(out) = chloride(in) +
CC         L-leucine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:71279, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:57427;
CC         Evidence={ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:20377526};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.79 mM for L-alanine (in the presence of CLTRN)
CC         {ECO:0000269|PubMed:26240152};
CC         KM=0.14 mM for L-alanine (in the presence of ACE2)
CC         {ECO:0000269|PubMed:26240152};
CC         KM=0.99 mM for L-glycine (in the presence of CLTRN)
CC         {ECO:0000269|PubMed:26240152};
CC         KM=0.27 mM for L-glycine (in the presence of ACE2)
CC         {ECO:0000269|PubMed:26240152};
CC         KM=0.9 mM for L-alanine (in the presence of CLTRN)
CC         {ECO:0000269|PubMed:20377526};
CC         KM=2.3 mM for L-glycine (in the presence of CLTRN)
CC         {ECO:0000269|PubMed:20377526};
CC   -!- SUBUNIT: Interacts with CLTRN; this interaction regulates the
CC       trafficking of SLC6A18 to the cell membrane and its activity.
CC       {ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:26240152}.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:19478081, ECO:0000269|PubMed:20377526}; Multi-pass
CC       membrane protein {ECO:0000255}. Cell membrane
CC       {ECO:0000269|PubMed:20377526, ECO:0000269|PubMed:26240152}; Multi-pass
CC       membrane protein {ECO:0000255}. Note=In kidneys localizes to the apical
CC       membrane in distal segments of the proximal tubule (PubMed:19478081,
CC       PubMed:20377526). Cell membrane expression is CLTRN-dependent
CC       (PubMed:20377526). {ECO:0000269|PubMed:19478081,
CC       ECO:0000269|PubMed:20377526}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=A12;
CC         IsoId=O88576-1; Sequence=Displayed;
CC       Name=2; Synonyms=A11;
CC         IsoId=O88576-2; Sequence=VSP_050365;
CC       Name=3; Synonyms=B11;
CC         IsoId=O88576-3; Sequence=VSP_050364;
CC       Name=4; Synonyms=A10;
CC         IsoId=O88576-4; Sequence=VSP_050366, VSP_050367;
CC       Name=5; Synonyms=B9;
CC         IsoId=O88576-5; Sequence=VSP_050364, VSP_050366, VSP_050367;
CC       Name=6; Synonyms=A8;
CC         IsoId=O88576-6; Sequence=VSP_050363, VSP_050697;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in kidney.
CC       {ECO:0000269|PubMed:9932288}.
CC   -!- DEVELOPMENTAL STAGE: Barely detectable at post natal day 0, reaching
CC       maximum expression after the third week of life.
CC       {ECO:0000269|PubMed:20377526}.
CC   -!- DISRUPTION PHENOTYPE: Animals lacking this protein exhibit no gross
CC       abnormalities and grow to adulthood, although they do exhibit
CC       hypertension. The elevated blood pressure appears to be attributable to
CC       a decreased level of renal glycine. High-affinity renal reabsorption of
CC       glycine is eliminated and intrarenal glycine concentration is reduced.
CC       {ECO:0000269|PubMed:15121838}.
CC   -!- SIMILARITY: Belongs to the sodium:neurotransmitter symporter (SNF)
CC       (TC 2.A.22) family. SLC6A18 subfamily. {ECO:0000305}.
CC   -!- CAUTION: Human SLC6A18 has been shown to be an inactive protein.
CC       {ECO:0000269|PubMed:26240152}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF075262; AAC27757.1; -; mRNA.
DR   EMBL; AF075263; AAC27758.1; -; mRNA.
DR   EMBL; AF075264; AAC27759.1; -; mRNA.
DR   EMBL; AF075265; AAC27760.1; -; mRNA.
DR   EMBL; AF075266; AAC27761.1; -; mRNA.
DR   EMBL; AF075267; AAC27762.1; -; mRNA.
DR   EMBL; BC010748; AAH10748.1; -; mRNA.
DR   CCDS; CCDS36727.1; -. [O88576-1]
DR   CCDS; CCDS49311.1; -. [O88576-3]
DR   CCDS; CCDS49312.1; -. [O88576-4]
DR   CCDS; CCDS88479.1; -. [O88576-5]
DR   CCDS; CCDS88481.1; -. [O88576-2]
DR   RefSeq; NP_001035782.1; NM_001040692.3. [O88576-1]
DR   RefSeq; NP_001129559.1; NM_001136087.2. [O88576-3]
DR   RefSeq; NP_001162115.1; NM_001168644.1. [O88576-4]
DR   RefSeq; NP_001162116.1; NM_001168645.1. [O88576-5]
DR   RefSeq; NP_001162117.1; NM_001168646.1. [O88576-2]
DR   AlphaFoldDB; O88576; -.
DR   SMR; O88576; -.
DR   DIP; DIP-60421N; -.
DR   IntAct; O88576; 1.
DR   STRING; 10090.ENSMUSP00000152525; -.
DR   GlyCosmos; O88576; 1 site, No reported glycans.
DR   GlyGen; O88576; 3 sites.
DR   iPTMnet; O88576; -.
DR   PhosphoSitePlus; O88576; -.
DR   jPOST; O88576; -.
DR   PaxDb; 10090-ENSMUSP00000022105; -.
DR   ProteomicsDB; 260802; -. [O88576-1]
DR   ProteomicsDB; 260803; -. [O88576-2]
DR   ProteomicsDB; 260804; -. [O88576-3]
DR   ProteomicsDB; 260805; -. [O88576-4]
DR   ProteomicsDB; 260806; -. [O88576-5]
DR   ProteomicsDB; 260807; -. [O88576-6]
DR   Antibodypedia; 1938; 96 antibodies from 23 providers.
DR   DNASU; 22598; -.
DR   Ensembl; ENSMUST00000109679.4; ENSMUSP00000105301.3; ENSMUSG00000021612.16. [O88576-4]
DR   Ensembl; ENSMUST00000109680.10; ENSMUSP00000105302.3; ENSMUSG00000021612.16. [O88576-3]
DR   Ensembl; ENSMUST00000220650.2; ENSMUSP00000152403.2; ENSMUSG00000021612.16. [O88576-5]
DR   Ensembl; ENSMUST00000222029.2; ENSMUSP00000152525.2; ENSMUSG00000021612.16. [O88576-1]
DR   Ensembl; ENSMUST00000223026.2; ENSMUSP00000152516.2; ENSMUSG00000021612.16. [O88576-6]
DR   Ensembl; ENSMUST00000223074.2; ENSMUSP00000152146.2; ENSMUSG00000021612.16. [O88576-2]
DR   GeneID; 22598; -.
DR   KEGG; mmu:22598; -.
DR   UCSC; uc007rds.2; mouse. [O88576-1]
DR   UCSC; uc007rdt.2; mouse. [O88576-2]
DR   UCSC; uc007rdu.2; mouse. [O88576-3]
DR   UCSC; uc007rdv.2; mouse. [O88576-4]
DR   UCSC; uc007rdw.2; mouse. [O88576-5]
DR   AGR; MGI:1336892; -.
DR   CTD; 348932; -.
DR   MGI; MGI:1336892; Slc6a18.
DR   VEuPathDB; HostDB:ENSMUSG00000021612; -.
DR   eggNOG; KOG3659; Eukaryota.
DR   GeneTree; ENSGT00940000158906; -.
DR   HOGENOM; CLU_006855_7_2_1; -.
DR   InParanoid; O88576; -.
DR   OMA; VLTWVMW; -.
DR   OrthoDB; 3084493at2759; -.
DR   PhylomeDB; O88576; -.
DR   TreeFam; TF343812; -.
DR   Reactome; R-MMU-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-MMU-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   BioGRID-ORCS; 22598; 2 hits in 75 CRISPR screens.
DR   ChiTaRS; Slc6a18; mouse.
DR   PRO; PR:O88576; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   RNAct; O88576; Protein.
DR   Bgee; ENSMUSG00000021612; Expressed in right kidney and 33 other cell types or tissues.
DR   ExpressionAtlas; O88576; baseline and differential.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031526; C:brush border membrane; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0015175; F:neutral L-amino acid transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0140931; F:neutral L-amino acid:sodium:chloride symporter activity; IDA:UniProtKB.
DR   GO; GO:0003333; P:amino acid transmembrane transport; IDA:MGI.
DR   GO; GO:0006836; P:neurotransmitter transport; IEA:UniProtKB-KW.
DR   GO; GO:0015804; P:neutral amino acid transport; IDA:UniProtKB.
DR   GO; GO:1990297; P:renal amino acid absorption; IMP:UniProtKB.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IBA:GO_Central.
DR   CDD; cd11517; SLC6sbd_B0AT3; 1.
DR   InterPro; IPR042701; B0AT3_SLC6sbd.
DR   InterPro; IPR000175; Na/ntran_symport.
DR   InterPro; IPR002438; Neutral_aa_SLC6.
DR   InterPro; IPR037272; SNS_sf.
DR   PANTHER; PTHR11616:SF109; INACTIVE SODIUM-DEPENDENT NEUTRAL AMINO ACID TRANSPORTER B(0)AT3; 1.
DR   PANTHER; PTHR11616; SODIUM/CHLORIDE DEPENDENT TRANSPORTER; 1.
DR   Pfam; PF00209; SNF; 1.
DR   PRINTS; PR00176; NANEUSMPORT.
DR   PRINTS; PR01206; ORPHTRNSPORT.
DR   SUPFAM; SSF161070; SNF-like; 1.
DR   PROSITE; PS00610; NA_NEUROTRAN_SYMP_1; 1.
DR   PROSITE; PS00754; NA_NEUROTRAN_SYMP_2; 1.
DR   PROSITE; PS50267; NA_NEUROTRAN_SYMP_3; 1.
DR   Genevisible; O88576; MM.
PE   1: Evidence at protein level;
KW   Alternative splicing; Amino-acid transport; Cell membrane; Glycoprotein;
KW   Membrane; Neurotransmitter transport; Reference proteome; Symport;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..615
FT                   /note="Sodium-dependent neutral amino acid transporter
FT                   B(0)AT3"
FT                   /id="PRO_0000214807"
FT   TOPO_DOM        1..26
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        27..47
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        48..52
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        53..73
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        74..105
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        106..126
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        127..177
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        178..198
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        199..206
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        207..227
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        228..255
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        256..276
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        277..288
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        289..309
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        310..397
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        398..418
FT                   /note="Helical; Name=8"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        419..441
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        442..462
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        463..472
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        473..493
FT                   /note="Helical; Name=10"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        494..520
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        521..541
FT                   /note="Helical; Name=11"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        542..570
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        571..591
FT                   /note="Helical; Name=12"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        592..615
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        143
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        167
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        353
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         377..444
FT                   /note="SASGPGLAFIVFTEAVLHMPGASVWSVLFFGMLFTLGLSSMFGNMEGVITPL
FT                   LDMGILPKGIPKEVMT -> PTWKQISGARVLGEGCARLTSRVCEASVLP (in
FT                   isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050364"
FT   VAR_SEQ         377..422
FT                   /note="SASGPGLAFIVFTEAVLHMPGASVWSVLFFGMLFTLGLSSMFGNME -> VL
FT                   LCGLCSSLGCCLPWVCPPCLGTWRVSLHHYWTWGSYPKVYPRRS (in isoform
FT                   6)"
FT                   /evidence="ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050363"
FT   VAR_SEQ         423..615
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050697"
FT   VAR_SEQ         445..454
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050365"
FT   VAR_SEQ         499..552
FT                   /note="FCDDIEWMTGRRPGLYWQVTWRVVSPMLLFGIFLSYIVLLIQTPPSYKAWNP
FT                   QY -> NIFPQERRSSTQAGCRSPVCSCPSCPHCGSLELLWLSYCPSTNRGGRLRIWKV
FT                   V (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050366"
FT   VAR_SEQ         553..615
FT                   /note="Missing (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:9932288"
FT                   /id="VSP_050367"
FT   MUTAGEN         21
FT                   /note="D->N: No effect on protein abundance. Increases
FT                   localization to the cell membrane. Increases alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         25
FT                   /note="Q->D: No effect on protein abundance. Almost
FT                   complete loss of cell surface localization. Decreases
FT                   alanine uptake activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         25
FT                   /note="Q->V: No effect on protein abundance. Strong
FT                   decrease of cell surface localization. Decreases alanine
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         50
FT                   /note="H->Y: No effect on protein abundance. No effect on
FT                   cell surface localization. Increases alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         72
FT                   /note="Y->H: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         78
FT                   /note="G->S: No effect on protein abundance. No effect on
FT                   cell surface expression. Decreases alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         90
FT                   /note="K->T: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         158
FT                   /note="S->D: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         213
FT                   /note="L->W: No effect on protein abundance. No effect on
FT                   cell surface localization. Decreases alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         225
FT                   /note="R->T: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         283
FT                   /note="N->D: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         287
FT                   /note="D->K: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         287
FT                   /note="D->N: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         296
FT                   /note="S->R: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         297
FT                   /note="M->C: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         297
FT                   /note="M->S: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         456
FT                   /note="I->T: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         464
FT                   /note="G->N: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         477
FT                   /note="L->P: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         495
FT                   /note="G->R: No effect on protein abundance. Strong
FT                   decreases of cell surface localization. Decreases alanine
FT                   uptake activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         502
FT                   /note="D->N: Decreases protein abundance. Strong decreases
FT                   of cell surface localization. Strong decreases on alanine
FT                   uptake activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
FT   MUTAGEN         568
FT                   /note="Q->R: No effect on protein abundance. No effect on
FT                   cell surface localization. No effect on alanine uptake
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26240152"
SQ   SEQUENCE   615 AA;  69229 MW;  A7925C0397FC63F8 CRC64;
     MAQASGMDPL VDIEDERPKW DNKLQYLLSC IGFAVGLGNI WRFPYLCQTH GGGAFLIPYF
     IALVFEGIPL FYIELAIGQR LRRGSIGVWK TISPYLGGVG LGCFSVSFLV SLYYNTVLLW
     VLWFFLNSFQ HPLPWSTCPL DLNRTGFVQE CQSSGTVSYF WYRQTLNITS DISNTGTIQW
     KLFLCLVACW STVYLCVIRG IESTGKVIYF TALFPYLVLT IFLIRGLTLP GATEGLIYLF
     TPNMKTLQNP RVWLDAATQI FFSLSLAFGG HIAFASYNPP RNNCEKDAVI IALVNSMTSL
     YASIAIFSVM GFKASNDYGR CLDRNILSLI NEFDLPELSI SRDEYPSVLM YLNATQTARV
     AQLPLKTCHL EDFLDKSASG PGLAFIVFTE AVLHMPGASV WSVLFFGMLF TLGLSSMFGN
     MEGVITPLLD MGILPKGIPK EVMTGVICFA CFLSAICFTL QSGGYWLEIF DSFAASLNLI
     IFAFMEVVGV IHIYGMKRFC DDIEWMTGRR PGLYWQVTWR VVSPMLLFGI FLSYIVLLIQ
     TPPSYKAWNP QYEHFPSREE KFYPGWVQVT CVLLSFLPSL WVPGVALAQL LSQYKQRWKA
     THLESGLKLQ ESRGC
//